{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:20Z","timestamp":1788262160336,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00277-025-06514-8","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:19:10Z","timestamp":1753949950000},"page":"4111-4120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor"],"prefix":"10.1007","volume":"104","author":[{"given":"Hyunkyung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonsuk","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Yeoun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonyang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"6514_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/jco.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D et al (2017) Long-Term Follow-Up of the French stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298\u2013305. https:\/\/doi.org\/10.1200\/jco.2016.68.2914","journal-title":"J Clin Oncol"},{"key":"6514_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/ajh.26556","volume":"97","author":"E Inzoli","year":"2022","unstructured":"Inzoli E, Aroldi A, Piazza R, Gambacorti-Passerini C (2022) Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success. Am J Hematol 97:1075\u20131085. https:\/\/doi.org\/10.1002\/ajh.26556","journal-title":"Am J Hematol"},{"key":"6514_CR3","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97:1236\u20131256. https:\/\/doi.org\/10.1002\/ajh.26642","journal-title":"Am J Hematol"},{"key":"6514_CR4","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1002\/cncr.31977","volume":"125","author":"M D\u2019Adda","year":"2019","unstructured":"D\u2019Adda M, Farina M, Schieppati F et al (2019) The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer 125:1674\u20131682. https:\/\/doi.org\/10.1002\/cncr.31977","journal-title":"Cancer"},{"key":"6514_CR5","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","volume":"102","author":"S Claudiani","year":"2017","unstructured":"Claudiani S, Apperley JF, Gale RP et al (2017) E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica 102:e297\u2013e299. https:\/\/doi.org\/10.3324\/haematol.2017.168740","journal-title":"Haematologica"},{"key":"6514_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s1470-2045(18)30192-x","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. https:\/\/doi.org\/10.1016\/s1470-2045(18)30192-x","journal-title":"Lancet Oncol"},{"key":"6514_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s11523-021-00831-4","volume":"16","author":"F Castagnetti","year":"2021","unstructured":"Castagnetti F, Binotto G, Capodanno I et al (2021) Making Treatment-Free remission (TFR) easier in chronic myeloid leukemia: Fact-Checking and practical management tools. Target Oncol 16:823\u2013838. https:\/\/doi.org\/10.1007\/s11523-021-00831-4","journal-title":"Target Oncol"},{"key":"6514_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Sch\u00fctz","year":"2017","unstructured":"Sch\u00fctz C, Inselmann S, Saussele S et al (2017) Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia 31:829\u2013836. https:\/\/doi.org\/10.1038\/leu.2017.9","journal-title":"Leukemia"},{"key":"6514_CR9","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z et al (2017) Natural killer-cell counts are associated with molecular relapse-free survival after Imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica 102:1368\u20131377. https:\/\/doi.org\/10.3324\/haematol.2017.165001","journal-title":"Haematologica"},{"key":"6514_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H et al (2017) Increased proportion of mature NK cells is associated with successful Imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108\u20131116. https:\/\/doi.org\/10.1038\/leu.2016.360","journal-title":"Leukemia"},{"key":"6514_CR11","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00277-021-04606-9","volume":"100","author":"J Kong","year":"2021","unstructured":"Kong J, Qin YZ, Zhao XS, Hou Y, Liu KY, Huang XJ, Jiang H (2021) Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Ann Hematol 100:2557\u20132566. https:\/\/doi.org\/10.1007\/s00277-021-04606-9","journal-title":"Ann Hematol"},{"key":"6514_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-1-4939-9904-0_10","volume":"2079","author":"A Goytain","year":"2020","unstructured":"Goytain A, Ng T (2020) NanoString nCounter technology: High-Throughput RNA validation. Methods Mol Biol 2079:125\u2013139. https:\/\/doi.org\/10.1007\/978-1-4939-9904-0_10","journal-title":"Methods Mol Biol"},{"key":"6514_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ijlh.12555","volume":"38","author":"D Hu","year":"2016","unstructured":"Hu D, Zhou W, Wang F et al (2016) Development of a NanoString assay to detect leukemogenic fusion transcripts in acute myeloid leukemia. Int J Lab Hematol 38:663\u2013673. https:\/\/doi.org\/10.1111\/ijlh.12555","journal-title":"Int J Lab Hematol"},{"key":"6514_CR14","doi-asserted-by":"publisher","first-page":"e0280364","DOI":"10.1371\/journal.pone.0280364","volume":"18","author":"A D\u2019Angelo","year":"2023","unstructured":"D\u2019Angelo A, Kilili H, Chapman R et al (2023) Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. PLoS ONE 18:e0280364. https:\/\/doi.org\/10.1371\/journal.pone.0280364","journal-title":"PLoS ONE"},{"key":"6514_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-022-00667-9","volume":"12","author":"S Adnan Awad","year":"2022","unstructured":"Adnan Awad S, Br\u00fcck O, Shanmuganathan N et al (2022) Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer J 12:69. https:\/\/doi.org\/10.1038\/s41408-022-00667-9","journal-title":"Blood Cancer J"},{"key":"6514_CR16","doi-asserted-by":"publisher","first-page":"204062072312056","DOI":"10.1177\/20406207231205637","volume":"14","author":"H Park","year":"2023","unstructured":"Park H, Kim HJ, Sohn SK et al (2023) Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor. Ther Adv Hematol 14:20406207231205637. https:\/\/doi.org\/10.1177\/20406207231205637","journal-title":"Ther Adv Hematol"},{"key":"6514_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/s1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al (2010) Discontinuation of Imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035. https:\/\/doi.org\/10.1016\/s1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"6514_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A et al (2020) Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma 61:650\u2013659. https:\/\/doi.org\/10.1080\/10428194.2019.1675879","journal-title":"Leuk Lymphoma"},{"key":"6514_CR19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"6514_CR20","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/s2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K et al (2020) Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol 7:e218\u2013e225. https:\/\/doi.org\/10.1016\/s2352-3026(19)30235-2","journal-title":"Lancet Haematol"},{"key":"6514_CR21","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/s2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2:e528\u2013535. https:\/\/doi.org\/10.1016\/s2352-3026(15)00196-9","journal-title":"Lancet Haematol"},{"key":"6514_CR22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","volume":"94","author":"CM Lucas","year":"2009","unstructured":"Lucas CM, Harris RJ, Giannoudis A et al (2009) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to Imatinib compared to patients with the e14a2 transcript. Haematologica 94:1362\u20131367. https:\/\/doi.org\/10.3324\/haematol.2009.009134","journal-title":"Haematologica"},{"key":"6514_CR23","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Rosti G, Soverini S (2019) Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia 33:2358\u20132364. https:\/\/doi.org\/10.1038\/s41375-019-0562-1","journal-title":"Leukemia"},{"key":"6514_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/ejh.13238","volume":"103","author":"L Kjaer","year":"2019","unstructured":"Kjaer L, Skov V, Andersen MT et al (2019) Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe against Cancer qPCR assay. Eur J Haematol 103:26\u201334. https:\/\/doi.org\/10.1111\/ejh.13238","journal-title":"Eur J Haematol"},{"key":"6514_CR25","doi-asserted-by":"publisher","unstructured":"Weis-Banke SE, Lisle TL, Perez-Penco M et al (2022) Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2022-005326","DOI":"10.1136\/jitc-2022-005326"},{"key":"6514_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3324\/haematol.2010.035006","volume":"97","author":"H Herrmann","year":"2012","unstructured":"Herrmann H, Cerny-Reiterer S, Gleixner KV et al (2012) CD34(+)\/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin. Haematologica 97:219\u2013226. https:\/\/doi.org\/10.3324\/haematol.2010.035006","journal-title":"Haematologica"},{"key":"6514_CR27","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1038\/s41467-019-10320-y","volume":"10","author":"T-J Kim","year":"2019","unstructured":"Kim T-J, Park G, Kim J et al (2019) CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nat Commun 10:3258. https:\/\/doi.org\/10.1038\/s41467-019-10320-y","journal-title":"Nat Commun"},{"key":"6514_CR28","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.Ccr-21-3594","volume":"28","author":"G Corradi","year":"2022","unstructured":"Corradi G, Bassani B, Simonetti G et al (2022) Release of IFN\u03b3 by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. Clin Cancer Res 28:3141\u20133155. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3594","journal-title":"Clin Cancer Res"},{"key":"6514_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-022-00369-1","volume":"10","author":"K-Y Jiang","year":"2022","unstructured":"Jiang K-Y, Qi L-L, Kang F-B, Wang L (2022) The intriguing roles of Siglec family members in the tumor microenvironment. Biomark Res 10:22. https:\/\/doi.org\/10.1186\/s40364-022-00369-1","journal-title":"Biomark Res"},{"key":"6514_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12859-022-04841-5","volume":"23","author":"H Shi","year":"2022","unstructured":"Shi H, Gao L, Zhang W, Jiang M (2022) Identification and validation of a siglec-based and aging-related 9-gene signature for predicting prognosis in acute myeloid leukemia patients. BMC Bioinformatics 23:284. https:\/\/doi.org\/10.1186\/s12859-022-04841-5","journal-title":"BMC Bioinformatics"},{"key":"6514_CR31","first-page":"8589","volume":"13","author":"X Hou","year":"2021","unstructured":"Hou X, Chen G, Zhao Y (2021) Research progress on CD169-positive macrophages in tumors. Am J Transl Res 13:8589\u20138597","journal-title":"Am J Transl Res"},{"key":"6514_CR32","doi-asserted-by":"publisher","first-page":"e1004380","DOI":"10.1371\/journal.ppat.1004380","volume":"10","author":"S Vigan\u00f2","year":"2014","unstructured":"Vigan\u00f2 S, Banga R, Bellanger F et al (2014) CD160-Associated CD8 T-Cell functional impairment is independent of PD-1 expression. PLoS Pathog 10:e1004380. https:\/\/doi.org\/10.1371\/journal.ppat.1004380","journal-title":"PLoS Pathog"},{"key":"6514_CR33","doi-asserted-by":"publisher","unstructured":"Ji H, Ba Y, Ma S et al (2021) Construction of Interferon-Gamma-Related gene signature to characterize the Immune-Inflamed phenotype of glioblastoma and predict prognosis, efficacy of immunotherapy and radiotherapy. 12. https:\/\/doi.org\/10.3389\/fimmu.2021.729359","DOI":"10.3389\/fimmu.2021.729359"},{"key":"6514_CR34","doi-asserted-by":"publisher","unstructured":"Vadakekolathu J, Minden MD, Hood T et al (2020) Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med 12. https:\/\/doi.org\/10.1126\/scitranslmed.aaz0463","DOI":"10.1126\/scitranslmed.aaz0463"},{"key":"6514_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11060-004-9165-3","volume":"70","author":"J Kouno","year":"2004","unstructured":"Kouno J, Nagai H, Nagahata T et al (2004) Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth. J Neurooncol 70:301\u2013307. https:\/\/doi.org\/10.1007\/s11060-004-9165-3","journal-title":"J Neurooncol"},{"key":"6514_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7537\/marslsj150418.01","volume":"15","author":"A Zaghloul","year":"2018","unstructured":"Zaghloul A, Morsi H, Ismail M, Teama S, Abdulateef N (2018) Soluble carcinoembryonic antigen cell adhesion molecule 1,6 and 8 in acute myeloid leukemia: their relation to survival and prognosis. Life Sci J 15:11. https:\/\/doi.org\/10.7537\/marslsj150418.01","journal-title":"Life Sci J"},{"key":"6514_CR37","doi-asserted-by":"publisher","first-page":"8454","DOI":"10.4049\/jimmunol.179.12.8454","volume":"179","author":"J Yoon","year":"2007","unstructured":"Yoon J, Terada A, Kita H (2007) CD66b regulates adhesion and activation of human eosinophils. J Immunol 179:8454\u20138462. https:\/\/doi.org\/10.4049\/jimmunol.179.12.8454","journal-title":"J Immunol"},{"key":"6514_CR38","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4161\/cbt.6.7.4327","volume":"6","author":"S Shaheduzzaman","year":"2007","unstructured":"Shaheduzzaman S, Vishwanath A, Furusato B et al (2007) Silencing of lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 6:1088\u20131095. https:\/\/doi.org\/10.4161\/cbt.6.7.4327","journal-title":"Cancer Biol Ther"},{"key":"6514_CR39","doi-asserted-by":"publisher","first-page":"944494","DOI":"10.3389\/fonc.2022.944494","volume":"12","author":"J Deng","year":"2022","unstructured":"Deng J, Jiang R, Meng E, Wu H (2022) CXCL5: A coachman to drive cancer progression. Front Oncol 12:944494. https:\/\/doi.org\/10.3389\/fonc.2022.944494","journal-title":"Front Oncol"},{"key":"6514_CR40","doi-asserted-by":"publisher","first-page":"18347","DOI":"10.1038\/s41598-019-54545-9","volume":"9","author":"R Pandey","year":"2019","unstructured":"Pandey R, Zhou M, Islam S et al (2019) Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in pancreatic ductal adenocarcinoma (PDA): an integrative analysis of a novel therapeutic target. Sci Rep 9:18347. https:\/\/doi.org\/10.1038\/s41598-019-54545-9","journal-title":"Sci Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06514-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06514-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06514-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:48:54Z","timestamp":1757663334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06514-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6514"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06514-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committees of each hospital. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}